{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:35:28Z","timestamp":1782333328278,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T00:00:00Z","timestamp":1305590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10072-011-0612-6","type":"journal-article","created":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T09:49:32Z","timestamp":1305539372000},"page":"1063-1067","source":"Crossref","is-referenced-by-count":9,"title":["Safety and tolerability of dapsone for the treatment of patients with drug-resistant, partial-onset seizures: an open-label trial"],"prefix":"10.1007","volume":"32","author":[{"given":"Mario","family":"L\u00f3pez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Diaz-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,17]]},"reference":[{"key":"612_CR1","unstructured":"Mandell GL, Petri WA Jr (1996) Drugs used in chemotherapy of tuberculosis, diseases caused by Mycobacterium avium and leprosy. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 9th edn. McGraw Hill, New York, pp 1155\u20131174"},{"key":"612_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0920-1211(91)90001-V","volume":"10","author":"K Hamada","year":"1991","unstructured":"Hamada K, Hiyoshi T, Kobayashi S et al (1991) Anticonvulsive effect of dapsone on amygdala-kindled seizures in rats and cats. Epilepsy Res 10:93\u2013102","journal-title":"Epilepsy Res"},{"key":"612_CR3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-0404.1992.tb04012.x","volume":"85","author":"S Ishida","year":"1992","unstructured":"Ishida S, Hamada K, Yagi K et al (1992) Comparing the anticonvulsive effects of dapsone on amygdala-kindled seizures and hippocampal-kindled seizures in rats. Acta Neurol Scand 85:132\u2013135","journal-title":"Acta Neurol Scand"},{"key":"612_CR4","first-page":"259","volume":"36","author":"C Rios","year":"1993","unstructured":"Rios C, Altagracia M, Kravzov J et al (1993) EEG evaluation of the anticonvulsive effect of dapsone in the kainic acid model of epilepsy. Proc West Pharmacol Soc 36:259\u2013261","journal-title":"Proc West Pharmacol Soc"},{"key":"612_CR5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0304-3940(94)90869-9","volume":"176","author":"M Altagracia","year":"1994","unstructured":"Altagracia M, Monroy-Noyola A, Osorio-Rico L et al (1994) Dapsone attenuates kainic acid-induced seizures in rats. Neurosci Lett 176:52\u201354","journal-title":"Neurosci Lett"},{"key":"612_CR6","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/AAC.38.10.2249","volume":"38","author":"M Dietrich","year":"1994","unstructured":"Dietrich M, Gaus W, Kern P et al (1994) An international randomized study with long-term follow-up of single versus combination chemotherapy of multibacillary leprosy. Antimicrob Agents Chemother 38:2249\u20132257","journal-title":"Antimicrob Agents Chemother"},{"key":"612_CR7","first-page":"95","volume":"40","author":"G Garcia-Arenas","year":"1997","unstructured":"Garcia-Arenas G, Flores-Murrieta FJ, Rios C (1997) Anticonvulsive effects of dapsone: interaction with phenytoin in the kainic acid modelo f seizures. Proc West Pharmacol Soc 40:95\u201396","journal-title":"Proc West Pharmacol Soc"},{"key":"612_CR8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003088-198611040-00003","volume":"11","author":"J Zuidema","year":"1986","unstructured":"Zuidema J, Hilbers-Modderman ES, Merkus FW (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11:299\u2013315","journal-title":"Clin Pharmacokinet"},{"key":"612_CR9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pbc.20164","volume":"44","author":"S Williams","year":"2005","unstructured":"Williams S, MacDonald P, Hoyer JD et al (2005) Methemoglobinemia in children with acute lymphoblastic leukemia receiving dapsone for Pneumocystis carinii pneumonia prophylaxis: a correlation with cytochrome b5 reductase and enzyme levels. Pediatr Blood Cancer 44:55\u201362","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"612_CR10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1212\/WNL.43.11.2292","volume":"43","author":"The US Gabapentin-Study Group No. 5","year":"1993","unstructured":"The US Gabapentin-Study Group No. 5 (1993) Gabapentin as add-on therapy for refractory partial epilepsy: a double-blind placebo controlled parallel-group study. Neurology 43(11):2292\u20132298","journal-title":"Neurology"},{"key":"612_CR11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","volume":"35","author":"H Anhut","year":"1994","unstructured":"Anhut H, Ashman P, Feuerstein TJ et al (1994) Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind placebo controlled study. The International Gabapentin Study Group. Epilepsia 35:795\u2013801","journal-title":"Epilepsia"},{"key":"612_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1528-1157.1994.tb02920.x","volume":"35","author":"J Messenheimer","year":"1994","unstructured":"Messenheimer J, Ramsay RE, Willmore LJ (1994) Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 35:113\u2013121","journal-title":"Epilepsia"},{"key":"612_CR13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","volume":"46","author":"E Faught","year":"1996","unstructured":"Faught E, Wilder BJ, Ramsay RE et al (1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400- and 600-mg daily dosages: Topiramate YD Study Group. Neurology 46:1684\u20131690","journal-title":"Neurology"},{"key":"612_CR14","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","volume":"41","author":"SD Shorvon","year":"2000","unstructured":"Shorvon SD, L\u00f6wenthal A, Janz D et al (2000) Multicenter double-blind randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsy 41:1179\u20131186","journal-title":"Epilepsy"},{"key":"612_CR15","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.2174\/092986709789057635","volume":"16","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Zhou ZW, Yang LP et al (2009) Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16:3480\u20133675","journal-title":"Curr Med Chem"},{"key":"612_CR16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","volume":"45","author":"YI Zhu","year":"2001","unstructured":"Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45:420\u2013434","journal-title":"J Am Acad Dermatol"},{"key":"612_CR17","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","volume":"13","author":"IE Leppik","year":"2004","unstructured":"Leppik IE (2004) Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13:S5\u2013S9","journal-title":"Seizure"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-011-0612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-011-0612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-011-0612-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:19:31Z","timestamp":1559121571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-011-0612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,17]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s10072-011-0612-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,17]]}}}